Gotowa bibliografia na temat „Pharmaceutical Benefits Scheme”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Pharmaceutical Benefits Scheme”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Pharmaceutical Benefits Scheme"
Feras, Peter M. "Pharmaceutical Benefits Scheme". Medical Journal of Australia 145, nr 8 (październik 1986): 427. http://dx.doi.org/10.5694/j.1326-5377.1986.tb112410.x.
Pełny tekst źródłaLouis, W. J., C. J. O'Callaghan, H. Krum, A. G. Mander i E. S. B. Louis. "Pharmaceutical Benefits Scheme". Medical Journal of Australia 161, nr 2 (lipiec 1994): 174. http://dx.doi.org/10.5694/j.1326-5377.1994.tb127364.x.
Pełny tekst źródłaSnyder, Raymond D. "The Pharmaceutical Benefits Scheme". Medical Journal of Australia 149, nr 7 (październik 1988): 394. http://dx.doi.org/10.5694/j.1326-5377.1988.tb120688.x.
Pełny tekst źródłaWebb, John, i R. G. Robinson. "The Pharmaceutical Benefits Scheme". Medical Journal of Australia 149, nr 7 (październik 1988): 394. http://dx.doi.org/10.5694/j.1326-5377.1988.tb120689.x.
Pełny tekst źródłaColquhoun, D. M. "The Pharmaceutical Benefits Scheme". Medical Journal of Australia 149, nr 7 (październik 1988): 394–95. http://dx.doi.org/10.5694/j.1326-5377.1988.tb120690.x.
Pełny tekst źródłaMcLean, Allan. "The Pharmaceutical Benefits Scheme". Medical Journal of Australia 149, nr 7 (październik 1988): 395. http://dx.doi.org/10.5694/j.1326-5377.1988.tb120691.x.
Pełny tekst źródłaShaw, John. "The Pharmaceutical Benefits Scheme". Medical Journal of Australia 149, nr 7 (październik 1988): 395–96. http://dx.doi.org/10.5694/j.1326-5377.1988.tb120692.x.
Pełny tekst źródłaMcLean, Allan. "The Pharmaceutical Benefits Scheme". Medical Journal of Australia 149, nr 11-12 (grudzień 1988): 716. http://dx.doi.org/10.5694/j.1326-5377.1988.tb120842.x.
Pełny tekst źródłaShaw, John. "The Pharmaceutical Benefits Scheme". Medical Journal of Australia 149, nr 11-12 (grudzień 1988): 716. http://dx.doi.org/10.5694/j.1326-5377.1988.tb120843.x.
Pełny tekst źródłaLouis, W. J., C. J. O'Callaghan, H. Krum, A. G. Mander i E. S. B. Louis. "Pharmaceutical Benefits Scheme (PBS)". Medical Journal of Australia 160, nr 5 (marzec 1994): 306–7. http://dx.doi.org/10.5694/j.1326-5377.1994.tb125843.x.
Pełny tekst źródłaRozprawy doktorskie na temat "Pharmaceutical Benefits Scheme"
Sweeny, Kim. "Accounting for growth in the Pharmaceutical Benefits Scheme". Thesis, full-text, 2008. https://vuir.vu.edu.au/1960/.
Pełny tekst źródłaSweeny, Kim. "Accounting for growth in the Pharmaceutical Benefits Scheme". full-text, 2008. http://eprints.vu.edu.au/1960/1/sweeny.pdf.
Pełny tekst źródłaBlanch, Bianca. "What is normal? A critical analysis of the methods quantifying prescription drug use and potential misuse in pharmaceutical claims". Thesis, The University of Sydney, 2016. http://hdl.handle.net/2123/16910.
Pełny tekst źródłaSchofield, Deborah, i n/a. "Modelling health care expenditure : a new microsimulation approach to simulating the distributional impact of the Pharmaceutical Benefits Scheme". University of Canberra. Information Sciences & Engineering, 1999. http://erl.canberra.edu.au./public/adt-AUC20061107.171802.
Pełny tekst źródłaDonnelly, Neil James Public Health & Community Medicine Faculty of Medicine UNSW. "The use of interrupted time series analysis to evaluate the impact of Pharmaceutical Benefits Scheme policies on drug utilisation in Australia". Awarded by:University of New South Wales. Public Health and Community Medicine, 2005. http://handle.unsw.edu.au/1959.4/22509.
Pełny tekst źródłaLee, Kah Seng. "The impact of cost containment reforms to the Pharmaceutical Benefits Scheme (PBS) on prescribing volumes and expenditure in Australia: 1992-2011". Thesis, Curtin University, 2014. http://hdl.handle.net/20.500.11937/836.
Pełny tekst źródłaMak, Christine Suet Yee. "Evaluation of health programs: application of social cost benefit analysis in the Pharmaceutical Benefits Scheme listing of Australia". Thesis, 2005. https://vuir.vu.edu.au/15635/.
Pełny tekst źródłaNeville, Warwick John. "Healing the nation : access to medicines under the Pharmaceutical Benefits Scheme - the jurisprudence from history". Phd thesis, 2007. http://hdl.handle.net/1885/150188.
Pełny tekst źródłaLu, Christine Yi-Ju Medical Sciences Faculty of Medicine UNSW. "An examination of systems of access to important high cost medicines: a critical analysis of the nationally subsidised scheme of access to tumour necrosis factor inhibitors in Australia". 2007. http://handle.unsw.edu.au/1959.4/40579.
Pełny tekst źródłaSearles, Andrew. "A preliminary analysis of the pharmaceutical provisions in the Australia-United States Free Trade Agreement on prescription medicines in Australia". Thesis, 2010. http://hdl.handle.net/1959.13/44658.
Pełny tekst źródłaIn January 2005 Australia implemented the Australia-United States Free Trade Agreement (AUSFTA). The AUSFTA was a historic document because it laid out a closer trading association between Australia and its close ally, the United States (US). The Agreement was generally welcomed in both countries but it contained provisions that were controversial, perhaps none more so than those covering pharmaceuticals. In Australia there was deep concern over the effects of these provisions on the Pharmaceutical Benefits Scheme (PBS). A Senate Committee investigating the likely impact of the AUSFTA was apprehensive that the provisions would result in the PBS paying higher prices for some medicines. The many outcomes from the research reported in this thesis are preliminary but amongst them, three stood out. First, the AUSFTA instituted a number of small but significant changes to Australian pharmaceutical policies and processes. Some changes, around transparency and listing times, were positive while others, such as sponsor hearings before the PBAC, will probably have limited negative impact. Second, there is now a need to consider the AUSFTA commitments when Australian health policy is reassessed in the future, which will now make Australia’s regulatory processes more complex. Third, it is argued that the AUSFTA may have had input into major reforms of the Australian PBS. These reforms delivered on an outcome that had been sought by the US: a weakening of reference pricing as used by the Australian PBS. The benefit from the change to reference pricing for Australia is unclear, but the PBS is now more vulnerable to higher prices for new medicines in the future.
Książki na temat "Pharmaceutical Benefits Scheme"
Office, New Zealand Audit. Department of Health: Administration of the pharmaceutical benefits scheme. Wellington, N.Z: The Office, 1992.
Znajdź pełny tekst źródłaZealand, New. Department of Health: Administration of the pharmaceutical benefits scheme. The Office, 1992.
Znajdź pełny tekst źródłaAustralia. Dept. of Finance. i Australian National Audit Office, red. Joint review by the Auditor-General and the Department of Finance: Pharmaceutical benefits scheme, review of estimated savings from proposed system for eligibility checking. Canberra: Australian Govt. Pub. Service, 1991.
Znajdź pełny tekst źródłaOlsen, Jan Abel. The healthcare delivery system: an overview. Oxford University Press, 2017. http://dx.doi.org/10.1093/oso/9780198794837.003.0013.
Pełny tekst źródłaCzęści książek na temat "Pharmaceutical Benefits Scheme"
Karanges, Emily A., Melisa J. Litchfield, Leigh Mellish i Sallie-Anne Pearson. "The Australian Pharmaceutical Benefits Scheme (PBS) Dispensing Database". W Databases for Pharmacoepidemiological Research, 255–66. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-51455-6_21.
Pełny tekst źródłaEpp, Joanne, Bonny Parkinson i Sally Hawse. "Health System Sustainability: The Pharmaceutical Benefits Scheme in Australia". W Industry and Higher Education, 13–44. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-0874-5_2.
Pełny tekst źródłaHuang, Weng-Foung, i Hung-Chi Chiang. "Pharmaceutical Benefit Scheme and Cost Containment in Taiwan's National Health Insurance". W International Drug Regulatory Mechanisms, 132–49. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003063858-7.
Pełny tekst źródłaLöfgren, Hans, i Ken Harvey. "The Pharmaceutical Benefits Scheme". W Understanding the Australian Health Care System, 71–82. Elsevier, 2009. http://dx.doi.org/10.1016/b978-0-7295-3861-9.10007-9.
Pełny tekst źródłaJackson, John. "Pharmaceutical Benefits Scheme (Australia)". W Encyclopedia of Clinical Pharmacy (Print), 688–91. CRC Press, 2002. http://dx.doi.org/10.1201/b13789-119.
Pełny tekst źródłaJackson, John K. "Pharmaceutical Benefits Scheme (Australia)". W Encyclopedia of Clinical Pharmacy, 688–91. Informa Healthcare, 2002. http://dx.doi.org/10.3109/9780824706081.118.
Pełny tekst źródłade Boer, Rebecca. "Reform of the pharmaceutical benefits scheme". W Analysing Health Policy, 214–24. Elsevier, 2008. http://dx.doi.org/10.1016/b978-0-7295-3843-5.50017-x.
Pełny tekst źródła"A War of Attrition: the Fate of the Pharmaceutical Benefits Scheme". W The Price of Health, 209–32. Cambridge University Press, 1991. http://dx.doi.org/10.1017/cbo9780511470189.010.
Pełny tekst źródłaRaymond, Chris, i Brett Parsons. "Chapter 9 Modelling Medicare and Pharmaceutical Benefits Scheme (PBS) Utilisation and Costs". W Modelling our Future - Population Ageing, Health and Aged Care, 197–211. Elsevier, 2007. http://dx.doi.org/10.1016/s1571-0386(06)16009-3.
Pełny tekst źródłaAbello, Annie, i Laurie Brown. "Model 18 MediSim (Static Microsimulation Model of the Australian Pharmaceutical Benefits Scheme)". W Modelling our Future - Population Ageing, Health and Aged Care, 533–39. Elsevier, 2007. http://dx.doi.org/10.1016/s1571-0386(06)16037-8.
Pełny tekst źródłaStreszczenia konferencji na temat "Pharmaceutical Benefits Scheme"
Khan, Arif, Uma Srinivasan i Shahadat Uddin. "Development and exploration of polymedication network from Pharmaceutical and Medicare Benefits Scheme data". W ACSW 2019: Australasian Computer Science Week 2019. New York, NY, USA: ACM, 2019. http://dx.doi.org/10.1145/3290688.3290738.
Pełny tekst źródła